Market share of Russian-made cancer drugs reached 75-80% within three years

Print 16 June 2017
GMP News

The share of Russian-made drugs for treatment and prevention of oncological diseases in the domestic market reached 75-80% in three years. This was announced by Mikhail Davydov, the part-time oncologist of the Ministry of Health of the Russian Federation and Director of N.N. Blokhin Russian Cancer Research Center.

“Only three years ago, about 90% of the market was held by imported drugs. Today, we observe the opposite – there is the rapid growth of Russian pharmaceutical industry and approximately 75-80% of drugs on the market are made in Russia. These are mostly generic drugs, which are used for manufacturing after the expiration of their original license,” said Mr. Davydov.

According to him, the problem of drug availability has been resolved in a “satisfactory way.” The lack of state financing for providing of expensive medicines to the patients for a long time is now being addressed, among other things, through sponsorship, added the chief oncologist of Russia.

Source

Return